Medindia

X

Don't Let More Animals Suffer and Die for Tobacco Products: PETA To FDA

by Rukmani Krishna on  June 7, 2012 at 11:32 PM General Health News   - G J E 4
Official comments were submitted by PETA today to the Food and Drug Administration (FDA) regarding the agency's Draft Guidance for Industry: Modified Risk Tobacco Product [MRTP] Applications, which, as currently written, will lead to animal studies being conducted in support of MRTP applications. Along with hundreds of consumers, PETA who submitted comments to the FDA through an action alert on PETA's popular website, is calling on the FDA to amend its guidance to recommend using only modern, effective non-animal testing methods—including computer simulation, tests using human cells, and clinical studies with human smokers—that are widely available and are the required tests in Canada. Belgium, Germany, the U.K and other countries have all banned the testing of tobacco products on animals.
 Don't Let More Animals Suffer and Die for Tobacco Products: PETA To FDA
Don't Let More Animals Suffer and Die for Tobacco Products: PETA To FDA
Advertisement

"Everyone knows that tobacco products are inherently hazardous, addictive, and deadly and that decades of animal tests did not predict the link between smoking and cancer," says PETA Vice President of Laboratory Investigations Kathy Guillermo. "PETA is calling on the FDA to make it clear, once and for all, that no more animals should suffer and die in tests for new tobacco products, 'less harmful' or not."

Advertisement
PETA recommends evaluation of toxicity in vitro be completed and submitted and MRTP applications be made public prior to commencement of any further studies, since many products will be similar to other tobacco products currently on the market, perhaps differing only in the concentration of one or more constituents already known to be harmful or potentially harmful. Laboratory analyses and evaluation in vitro should suffice to identify products of this type that are particularly risky or lack potential to reduce risk and harm. Development of such products need proceed no further, since any additional studies would be unlikely to restore confidence. For products that are not particularly risky, it should be possible to select clinical exposures that are not more risky than those from study participants' current tobacco use without first conducting animal studies.
Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All